gareth lilly pharma consulting limited
gareth lilly pharma consulting limited Company Information
Group Structure
View All
Industry
Other business support service activities n.e.c.
Registered Address
6 blackthorn drive, thatcham, west berkshire, RG18 4BW
Website
glpc.eugareth lilly pharma consulting limited Estimated Valuation
Pomanda estimates the enterprise value of GARETH LILLY PHARMA CONSULTING LIMITED at £263.5k based on a Turnover of £653.7k and 0.4x industry multiple (adjusted for size and gross margin).
gareth lilly pharma consulting limited Estimated Valuation
Pomanda estimates the enterprise value of GARETH LILLY PHARMA CONSULTING LIMITED at £176.2k based on an EBITDA of £59.7k and a 2.95x industry multiple (adjusted for size and gross margin).
gareth lilly pharma consulting limited Estimated Valuation
Pomanda estimates the enterprise value of GARETH LILLY PHARMA CONSULTING LIMITED at £613.8k based on Net Assets of £287.8k and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Gareth Lilly Pharma Consulting Limited Overview
Gareth Lilly Pharma Consulting Limited is a live company located in west berkshire, RG18 4BW with a Companies House number of 09193052. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in August 2014, it's largest shareholder is gareth lilly with a 100% stake. Gareth Lilly Pharma Consulting Limited is a established, small sized company, Pomanda has estimated its turnover at £653.7k with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Gareth Lilly Pharma Consulting Limited Health Check
Pomanda's financial health check has awarded Gareth Lilly Pharma Consulting Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
5 Weak
Size
annual sales of £653.7k, make it smaller than the average company (£3.7m)
- Gareth Lilly Pharma Consulting Limited
£3.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 18%, show it is growing at a faster rate (5.1%)
- Gareth Lilly Pharma Consulting Limited
5.1% - Industry AVG
Production
with a gross margin of 17.4%, this company has a higher cost of product (38.2%)
- Gareth Lilly Pharma Consulting Limited
38.2% - Industry AVG
Profitability
an operating margin of 9.1% make it more profitable than the average company (6.1%)
- Gareth Lilly Pharma Consulting Limited
6.1% - Industry AVG
Employees
with 1 employees, this is below the industry average (23)
1 - Gareth Lilly Pharma Consulting Limited
23 - Industry AVG
Pay Structure
on an average salary of £48.2k, the company has an equivalent pay structure (£48.2k)
- Gareth Lilly Pharma Consulting Limited
£48.2k - Industry AVG
Efficiency
resulting in sales per employee of £653.7k, this is more efficient (£152.6k)
- Gareth Lilly Pharma Consulting Limited
£152.6k - Industry AVG
Debtor Days
it gets paid by customers after 181 days, this is later than average (40 days)
- Gareth Lilly Pharma Consulting Limited
40 days - Industry AVG
Creditor Days
its suppliers are paid after 24 days, this is quicker than average (33 days)
- Gareth Lilly Pharma Consulting Limited
33 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Gareth Lilly Pharma Consulting Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Gareth Lilly Pharma Consulting Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 11.3%, this is a lower level of debt than the average (61.4%)
11.3% - Gareth Lilly Pharma Consulting Limited
61.4% - Industry AVG
GARETH LILLY PHARMA CONSULTING LIMITED financials
Gareth Lilly Pharma Consulting Limited's latest turnover from August 2023 is estimated at £653.7 thousand and the company has net assets of £287.8 thousand. According to their latest financial statements, Gareth Lilly Pharma Consulting Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | 1 | 1 | |||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 18 | 636 | 1,253 | ||||||
| Intangible Assets | |||||||||
| Investments & Other | |||||||||
| Debtors (Due After 1 year) | |||||||||
| Total Fixed Assets | 18 | 636 | 1,253 | ||||||
| Stock & work in progress | |||||||||
| Trade Debtors | 324,246 | 275,884 | 225,568 | 187,608 | 137,175 | 120,621 | 106,495 | 9,405 | 17,213 |
| Group Debtors | |||||||||
| Misc Debtors | |||||||||
| Cash | 70,447 | 39,242 | |||||||
| misc current assets | |||||||||
| total current assets | 324,246 | 275,884 | 225,568 | 187,608 | 137,175 | 120,621 | 106,495 | 79,852 | 56,455 |
| total assets | 324,264 | 276,520 | 226,821 | 187,608 | 137,175 | 120,621 | 106,495 | 79,852 | 56,455 |
| Bank overdraft | |||||||||
| Bank loan | |||||||||
| Trade Creditors | 36,504 | 33,548 | 35,543 | 38,351 | 32,063 | 35,128 | 37,264 | 32,627 | 25,138 |
| Group/Directors Accounts | |||||||||
| other short term finances | |||||||||
| hp & lease commitments | |||||||||
| other current liabilities | |||||||||
| total current liabilities | 36,504 | 33,548 | 35,543 | 38,351 | 32,063 | 35,128 | 37,264 | 32,627 | 25,138 |
| loans | |||||||||
| hp & lease commitments | |||||||||
| Accruals and Deferred Income | |||||||||
| other liabilities | |||||||||
| provisions | |||||||||
| total long term liabilities | |||||||||
| total liabilities | 36,504 | 33,548 | 35,543 | 38,351 | 32,063 | 35,128 | 37,264 | 32,627 | 25,138 |
| net assets | 287,760 | 242,972 | 191,278 | 149,257 | 105,112 | 85,493 | 69,231 | 47,225 | 31,317 |
| total shareholders funds | 287,760 | 242,972 | 191,278 | 149,257 | 105,112 | 85,493 | 69,231 | 47,225 | 31,317 |
| Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 | Aug 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | |||||||||
| Amortisation | |||||||||
| Tax | |||||||||
| Stock | |||||||||
| Debtors | 48,362 | 50,316 | 37,960 | 50,433 | 16,554 | 14,126 | 97,090 | -7,808 | 17,213 |
| Creditors | 2,956 | -1,995 | -2,808 | 6,288 | -3,065 | -2,136 | 4,637 | 7,489 | 25,138 |
| Accruals and Deferred Income | |||||||||
| Deferred Taxes & Provisions | |||||||||
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | |||||||||
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | |||||||||
| Group/Directors Accounts | |||||||||
| Other Short Term Loans | |||||||||
| Long term loans | |||||||||
| Hire Purchase and Lease Commitments | |||||||||
| other long term liabilities | |||||||||
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | -70,447 | 31,205 | 39,242 | ||||||
| overdraft | |||||||||
| change in cash | -70,447 | 31,205 | 39,242 |
gareth lilly pharma consulting limited Credit Report and Business Information
Gareth Lilly Pharma Consulting Limited Competitor Analysis
Perform a competitor analysis for gareth lilly pharma consulting limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other small companies, companies in RG18 area or any other competitors across 12 key performance metrics.
gareth lilly pharma consulting limited Ownership
GARETH LILLY PHARMA CONSULTING LIMITED group structure
Gareth Lilly Pharma Consulting Limited has no subsidiary companies.
Ultimate parent company
GARETH LILLY PHARMA CONSULTING LIMITED
09193052
gareth lilly pharma consulting limited directors
Gareth Lilly Pharma Consulting Limited currently has 1 director, Dr Gareth Lilly serving since Aug 2014.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Gareth Lilly | United Kingdom | 54 years | Aug 2014 | - | Director |
P&L
August 2023turnover
653.7k
-12%
operating profit
59.7k
0%
gross margin
17.5%
+3.42%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
August 2023net assets
287.8k
+0.18%
total assets
324.3k
+0.17%
cash
0
0%
net assets
Total assets minus all liabilities
gareth lilly pharma consulting limited company details
company number
09193052
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
August 2014
age
11
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
August 2023
previous names
N/A
accountant
-
auditor
-
address
6 blackthorn drive, thatcham, west berkshire, RG18 4BW
Bank
CATER ALLEN LTD
Legal Advisor
-
gareth lilly pharma consulting limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to gareth lilly pharma consulting limited.
gareth lilly pharma consulting limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GARETH LILLY PHARMA CONSULTING LIMITED. This can take several minutes, an email will notify you when this has completed.
gareth lilly pharma consulting limited Companies House Filings - See Documents
| date | description | view/download |
|---|
